应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PSNL Personalis
已收盘 07-21 16:00:00 EDT
13.44
+0.10
+0.75%
盘后
13.30
-0.14
-1.04%
19:34 EDT
最高
13.75
最低
12.94
成交量
681.23万
今开
13.30
昨收
13.34
日振幅
6.07%
总市值
14.06亿
流通市值
9.16亿
总股本
1.05亿
成交额
9,094万
换手率
10.00%
流通股本
6,812万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
股东权益律所对Personalis收购案启动调查
环球市场播报 · 03:43
股东权益律所对Personalis收购案启动调查
Tempus AI拟以15亿美元收购癌症检测公司Personalis
格隆汇 · 07-21 09:17
Tempus AI拟以15亿美元收购癌症检测公司Personalis
Tempus AI收购Personalis将分子残留病灶(MRD)深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers
智通财经 · 07-20 20:39
Tempus AI收购Personalis将分子残留病灶(MRD)深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers
报道称Tempus AI将以每股16.25美元的价格收购Personalis
老虎资讯综合 · 07-20 20:35
报道称Tempus AI将以每股16.25美元的价格收购Personalis
Tempus AI将收购Personalis,进一步整合分子残留病灶检测至其AI驱动的精准肿瘤学平台
美股速递 · 07-20 20:32
Tempus AI将收购Personalis,进一步整合分子残留病灶检测至其AI驱动的精准肿瘤学平台
Personalis公司公告:CMS扩大Medicare对NeXT Personal乳腺癌监测检测的覆盖范围
美股速递 · 05-21
Personalis公司公告:CMS扩大Medicare对NeXT Personal乳腺癌监测检测的覆盖范围
Personalis再获医保覆盖决定,Next Personal®拓展至乳腺癌术前治疗监测
美股速递 · 05-20
Personalis再获医保覆盖决定,Next Personal®拓展至乳腺癌术前治疗监测
Personalis公司 - 覆盖范围现已纳入II-III期TNBC或HER2+乳腺癌新辅助治疗监测
美股速递 · 05-20
Personalis公司 - 覆盖范围现已纳入II-III期TNBC或HER2+乳腺癌新辅助治疗监测
Personalis旗下Next Personal®获医保覆盖,用于晚期实体瘤免疫治疗监测
美股速递 · 05-13
Personalis旗下Next Personal®获医保覆盖,用于晚期实体瘤免疫治疗监测
Personalis, Inc.盘中异动 快速下跌5.49%报10.63美元
市场透视 · 01-23
Personalis, Inc.盘中异动 快速下跌5.49%报10.63美元
Personalis, Inc.盘中异动 大幅下挫5.80%报3.90美元
市场透视 · 2025-03-10
Personalis, Inc.盘中异动 大幅下挫5.80%报3.90美元
Personalis, Inc.2024财年实现净利润-81.28百万美元,同比增加24.74%
市场透视 · 2025-03-08
Personalis, Inc.2024财年实现净利润-81.28百万美元,同比增加24.74%
Personalis, Inc.盘中异动 急速上涨5.11%报4.32美元
市场透视 · 2025-03-05
Personalis, Inc.盘中异动 急速上涨5.11%报4.32美元
Personalis, Inc.盘中异动 早盘股价大跌6.33%
市场透视 · 2025-03-04
Personalis, Inc.盘中异动 早盘股价大跌6.33%
Personalis, Inc.盘中异动 股价大跌5.19%
市场透视 · 2025-03-03
Personalis, Inc.盘中异动 股价大跌5.19%
Personalis, Inc.盘中异动 早盘股价大跌5.42%
市场透视 · 2025-02-28
Personalis, Inc.盘中异动 早盘股价大跌5.42%
Personalis第四季度每股亏损$0.23优于预期$0.28,销售额$1680万美元高于预期$1574万美元
财报速递 · 2025-02-28
Personalis第四季度每股亏损$0.23优于预期$0.28,销售额$1680万美元高于预期$1574万美元
Personalis, Inc.盘中异动 快速跳水5.13%报4.25美元
市场透视 · 2025-02-28
Personalis, Inc.盘中异动 快速跳水5.13%报4.25美元
Personalis, Inc.盘中异动 早盘股价大涨5.32%
市场透视 · 2025-02-26
Personalis, Inc.盘中异动 早盘股价大涨5.32%
Personalis, Inc.盘中异动 早盘股价大跌5.41%
市场透视 · 2025-02-24
Personalis, Inc.盘中异动 早盘股价大跌5.41%
加载更多
公司概况
公司名称:
Personalis
所属市场:
NASDAQ
上市日期:
--
主营业务:
Personalis, Inc.于2011年2月21日在特拉华州注册成立,并于2011年9月开始运营。该公司是一家不断发展的癌症基因组学公司,通过提供有关每位患者癌症和免疫反应的更全面的分子数据,改变下一代疗法的发展。该公司设计其NeXT平台以适应对癌症的复杂和不断发展的理解,为其生物制药客户提供有关所有大约20,000个人类基因以及免疫系统的信息,而许多癌症小组覆盖大约50到500个基因。他们还在开发一种补充液体活检分析,分析所有人类基因与目前可用的更集中的液体活检分析。通过结合技术创新,运营规模和监管差异化,他们的NeXT平台旨在帮助他们的客户获得对治疗反应和抗药性机制以及新的潜在治疗目标的新见解。
发行价格:
--
{"stockData":{"symbol":"PSNL","market":"US","secType":"STK","nameCN":"Personalis","latestPrice":13.44,"timestamp":1784664000000,"preClose":13.34,"halted":0,"volume":6812302,"hourTrading":{"tag":"盘后","latestPrice":13.3,"preClose":13.44,"latestTime":"19:34 EDT","volume":45167,"amount":606081.6348,"timestamp":1784676849898,"change":-0.14,"changeRate":-0.010417,"amplitude":0.017857},"delay":0,"changeRate":0.007496251874062942,"floatShares":68123900,"shares":104631832,"eps":-1.02483,"marketStatus":"已收盘","change":0.1,"latestTime":"07-21 16:00:00 EDT","open":13.3,"high":13.75,"low":12.94,"amount":90938965.790554,"amplitude":0.06072,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.02483,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784707200000},"marketStatusCode":5,"adr":0,"listingDate":1561003200000,"exchange":"NASDAQ","adjPreClose":13.34,"preHourTrading":{"tag":"盘前","latestPrice":13.32,"preClose":13.34,"latestTime":"09:29 EDT","volume":9154,"amount":122168.606604,"timestamp":1784640599999,"change":-0.02,"changeRate":-0.001499,"amplitude":0.017241},"postHourTrading":{"tag":"盘后","latestPrice":13.3,"preClose":13.44,"latestTime":"19:34 EDT","volume":45167,"amount":606081.6348,"timestamp":1784676849898,"change":-0.14,"changeRate":-0.010417,"amplitude":0.017857},"volumeRatio":0.849838,"impliedVol":0.38,"impliedVolPercentile":0.0398},"requestUrl":"/m/hq/s/PSNL","defaultTab":"news","newsList":[{"id":"2653200461","title":"股东权益律所对Personalis收购案启动调查","url":"https://stock-news.laohu8.com/highlight/detail?id=2653200461","media":"环球市场播报","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653200461?lang=zh_cn&edition=full","pubTime":"2026-07-22 03:43","pubTimestamp":1784662980,"startTime":"0","endTime":"0","summary":"多家股东权益律师事务所近日宣布,已对癌症检测公司Personalis拟被Tempus AI收购的交易展开调查,关注点集中在交易价格是否公允以及董事会是否履行了信义义务。 根据7月20日公布的协议,Tempus AI将以每股16.25美元的价格收购其尚未持有的全部Personalis流通股份。 Personalis是微量残留疾病检测领域的领先企业,其NeXT Personal检测技术以超灵敏度著称。两家公司预计交易将于2026年底或2027年初完成,尚需Personalis股东和监管机构批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-22/doc-iniirfsq8992740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653624208","title":"Tempus AI拟以15亿美元收购癌症检测公司Personalis","url":"https://stock-news.laohu8.com/highlight/detail?id=2653624208","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653624208?lang=zh_cn&edition=full","pubTime":"2026-07-21 09:17","pubTimestamp":1784596647,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ARKG","BK4611","PSNL","LU1861559042.SGD","BK4613","LU1861558580.USD","TEM","TEMT","HEAL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652155242","title":"Tempus AI收购Personalis将分子残留病灶(MRD)深度整合进AI 精准肿瘤治疗平台本次并购结合 Pers","url":"https://stock-news.laohu8.com/highlight/detail?id=2652155242","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652155242?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:39","pubTimestamp":1784551140,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1861558580.USD","BK4611","TEM","HEAL","BK4613","LU1861559042.SGD","BK4121","ARKG","TEMT","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196410748","title":"报道称Tempus AI将以每股16.25美元的价格收购Personalis","url":"https://stock-news.laohu8.com/highlight/detail?id=1196410748","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196410748?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:35","pubTimestamp":1784550902,"startTime":"0","endTime":"0","summary":"报道称医疗科技公司Tempus AI将以每股16.25美元的价格收购Personalis,受消息影响,Tempus AI 跌超6%,Personalis 盘前变化不大。","market":"us","thumbnail":"https://static.tigerbbs.com/2a3253accc7322a3db322a8557ee9834","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2a3253accc7322a3db322a8557ee9834"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"报道称Tempus AI将以每股16.25美元的价格收购Personalis","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEMT","PSNL","TEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158055416","title":"Tempus AI将收购Personalis,进一步整合分子残留病灶检测至其AI驱动的精准肿瘤学平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1158055416","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158055416?lang=zh_cn&edition=full","pubTime":"2026-07-20 20:32","pubTimestamp":1784550720,"startTime":"0","endTime":"0","summary":"Tempus AI宣布将收购Personalis,此举旨在将其分子残留病灶检测技术更深度地整合到自身由人工智能赋能的精准肿瘤学平台之中。通过这项收购,Tempus AI计划强化其在癌症诊疗领域的数据分析与临床洞察能力,为患者提供更为个性化和动态的监测方案。整合后的平台有望提升对癌症复发风险的评估精度,助力实现更早的干预与治疗调整。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","BK4121","PSNL","BK4611","HEAL","ARKG","BK4613","TEM","LU1861558580.USD","TEMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157870191","title":"Personalis公司公告:CMS扩大Medicare对NeXT Personal乳腺癌监测检测的覆盖范围","url":"https://stock-news.laohu8.com/highlight/detail?id=1157870191","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157870191?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:14","pubTimestamp":1779308067,"startTime":"0","endTime":"0","summary":"Personalis公司于提交给美国证券交易委员会的文件中披露,美国医疗保险和医疗补助服务中心已决定扩大Medicare对NeXT Personal检测在乳腺癌监测领域的保险覆盖范围。此项政策调整意味着,更多符合条件的乳腺癌患者将能够通过联邦医疗保险计划,获得由Personalis公司提供的NeXT Personal检测服务,用于疾病进展的监测与管理。监管覆盖范围的扩大,被视为对NeXT Personal检测临床效用与价值的重要认可,预计将为Personalis公司在肿瘤精准医疗市场的业务拓展带来积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199968641","title":"Personalis再获医保覆盖决定,Next Personal®拓展至乳腺癌术前治疗监测","url":"https://stock-news.laohu8.com/highlight/detail?id=1199968641","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199968641?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:08","pubTimestamp":1779271704,"startTime":"0","endTime":"0","summary":"生物科技公司Personalis宣布,其Next Personal®检测产品再次获得一项美国联邦医疗保险的覆盖决定。这是该产品获得的第四项医保覆盖决定,标志着其应用范围将进一步扩大至乳腺癌患者的术前治疗监测领域。此次覆盖决定的落地,意味着更多符合条件的乳腺癌患者在接受术前治疗时,能够通过该检测进行疗效监测与评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSNL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199508401","title":"Personalis公司 - 覆盖范围现已纳入II-III期TNBC或HER2+乳腺癌新辅助治疗监测","url":"https://stock-news.laohu8.com/highlight/detail?id=1199508401","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199508401?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:06","pubTimestamp":1779271590,"startTime":"0","endTime":"0","summary":"Personalis公司宣布,其服务覆盖范围现已扩展至包含II-III期三阴性乳腺癌或HER2阳性乳腺癌的新辅助治疗监测。这一进展意味着,该公司能够为处于该疾病阶段的患者提供更为精准的治疗效果追踪与评估服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109056932","title":"Personalis旗下Next Personal®获医保覆盖,用于晚期实体瘤免疫治疗监测","url":"https://stock-news.laohu8.com/highlight/detail?id=1109056932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109056932?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:05","pubTimestamp":1778666731,"startTime":"0","endTime":"0","summary":"Personalis公司宣布,其用于晚期实体瘤患者免疫治疗监测的Next Personal®检测产品,现已获得美国医疗保险(Medicare)的覆盖。\n此项决定意味着,符合条件的晚期实体瘤患者在接受免疫治疗期间,使用Next Personal®进行监测将可获得医保报销。该检测旨在通过分析循环肿瘤DNA(ctDNA),帮助评估患者对免疫疗法的反应,为临床决策提供重要信息。\n获得医保覆盖是公司产品商业化进程中的一个重要里程碑,有望提升该检测在临床实践中的可及性,并为更多患者提供精准的监测选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605407883","title":"Personalis, Inc.盘中异动 快速下跌5.49%报10.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605407883","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605407883?lang=zh_cn&edition=full","pubTime":"2026-01-23 23:18","pubTimestamp":1769181523,"startTime":"0","endTime":"0","summary":"北京时间2026年01月23日23时18分,Personalis, Inc.股票出现波动,股价急速下挫5.49%。Personalis, Inc.股票所在的生命科学行业中,整体跌幅为0.71%。其相关个股中,Biodesix, Inc.、Natera, Inc.、Mainz Biomed N.V.涨幅较大,Xwell, Inc.、纽勤、Biodesix, Inc.较为活跃,换手率分别为3.21%、2.22%、1.92%,振幅较大的相关个股有Advanced Biomed Inc.、Biodesix, Inc.、Ispecimen Inc.,振幅分别为14.78%、9.82%、9.61%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012323184497a329fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012323184497a329fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PSNL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518222648","title":"Personalis, Inc.盘中异动 大幅下挫5.80%报3.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518222648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518222648?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:34","pubTimestamp":1741613647,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时34分,Personalis, Inc.股票出现异动,股价急速下跌5.80%。截至发稿,该股报3.90美元/股,成交量2.5378万股,换手率0.03%,振幅2.33%。Personalis, Inc.股票所在的生命科学行业中,整体跌幅为0.38%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。其产品包括ImmunoID NeXT, NeXT Personal, NeXT Dx Test和其他制药研究解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213407a26a25ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310213407a26a25ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517455647","title":"Personalis, Inc.2024财年实现净利润-81.28百万美元,同比增加24.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517455647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517455647?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363250,"startTime":"0","endTime":"0","summary":"3月8日,Personalis, Inc.公布财报,公告显示公司2024财年净利润为-81.28百万美元,同比增加24.74%;其中营业收入为84.61百万美元,同比增加15.15%,每股基本收益为-1.37美元。从资产负债表来看,Personalis, Inc.总负债67.31百万美元,其中短期债务9.37百万美元,资产负债比为0.05,流动比率为0.07。机构评级:截至2025年3月8日,当前有4家机构对Personalis, Inc.目标价做出预测,其中目标均价为7.75美元,其中最低目标价为7.00美元,最高目标价为9.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000205abed6670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000205abed6670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517949953","title":"Personalis, Inc.盘中异动 急速上涨5.11%报4.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517949953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517949953?lang=zh_cn&edition=full","pubTime":"2025-03-05 23:51","pubTimestamp":1741189919,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日23时51分,Personalis, Inc.股票出现异动,股价大幅拉升5.11%。Personalis, Inc.股票所在的生命科学行业中,整体涨幅为0.34%。其相关个股中,Biodesix, Inc.、Neuronetics, Inc.、Oncocyte Corporation涨幅较大,Neuronetics, Inc.、Ispecimen Inc.、Grail, Inc.较为活跃,换手率分别为2.37%、2.00%、1.31%,振幅较大的相关个股有Bioaffinity Technologies, Inc.、Oncocyte Corporation、Neuronetics, Inc.,振幅分别为17.70%、16.61%、16.55%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305235159989d594f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305235159989d594f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516967074","title":"Personalis, Inc.盘中异动 早盘股价大跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516967074","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516967074?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:33","pubTimestamp":1741098785,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时33分,Personalis, Inc.股票出现波动,股价快速下挫6.33%。Personalis, Inc.股票所在的生命科学行业中,整体跌幅为0.09%。其相关个股中,Neuronetics, Inc.、Xwell, Inc.、Prenetics Global涨幅较大,Biodesix, Inc.、Ispecimen Inc.、Natera, Inc.较为活跃,换手率分别为2.03%、0.77%、0.71%,振幅较大的相关个股有Xwell, Inc.、安奈特保险、Neuronetics, Inc.,振幅分别为9.25%、6.97%、6.79%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223305963944d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223305963944d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516634046","title":"Personalis, Inc.盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634046","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516634046?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:49","pubTimestamp":1741013360,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时49分,Personalis, Inc.股票出现异动,股价快速下跌5.19%。Personalis, Inc.股票所在的生命科学行业中,整体跌幅为0.30%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。其产品包括ImmunoID NeXT, NeXT Personal, NeXT Dx Test和其他制药研究解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224920989a14a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224920989a14a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514637887","title":"Personalis, Inc.盘中异动 早盘股价大跌5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514637887","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514637887?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753074,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分,Personalis, Inc.股票出现波动,股价大幅跳水5.42%。Personalis, Inc.股票所在的生命科学行业中,整体涨幅为0.38%。其相关个股中,Oncocyte Corporation、Opko健康、安奈特保险涨幅较大,Ispecimen Inc.、Mainz Biomed N.V.、Prophase Labs, Inc.较为活跃,换手率分别为4.27%、0.71%、0.56%,振幅较大的相关个股有Radnet, Inc.、Medpace Holdings, Inc.、Castle Biosciences, Inc.,振幅分别为2.74%、2.10%、2.06%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223114abe0ea0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223114abe0ea0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159025803","title":"Personalis第四季度每股亏损$0.23优于预期$0.28,销售额$1680万美元高于预期$1574万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159025803","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159025803?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:05","pubTimestamp":1740690313,"startTime":"0","endTime":"0","summary":"Personalis报告季度每股亏损$0.23,优于分析师普遍预期的$0.28,超出17.86%。与去年同期每股亏损$0.54相比,增加了57.41%。与去年同期$1968万美元的销售额相比,减少了14.61%。以上内容来自Benzinga Earnings专栏,原文如下:$Personalis$ reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 17.86 percent. This is a 57.41 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $16.80 million which beat the analyst consensus estimate of $15.74 million by 6.75 percent. This is a 14.61 p","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Personalis第四季度每股亏损$0.23优于预期$0.28,销售额$1680万美元高于预期$1574万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514363563","title":"Personalis, Inc.盘中异动 快速跳水5.13%报4.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514363563","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514363563?lang=zh_cn&edition=full","pubTime":"2025-02-28 02:24","pubTimestamp":1740680659,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日02时24分,Personalis, Inc.股票出现异动,股价快速下挫5.13%。截至发稿,该股报4.25美元/股,成交量69.6791万股,换手率0.82%,振幅9.37%。Personalis, Inc.股票所在的生命科学行业中,整体跌幅为1.62%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。其产品包括ImmunoID NeXT, NeXT Personal, NeXT Dx Test和其他制药研究解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228022420abdfa34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228022420abdfa34a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4121","PSNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514851893","title":"Personalis, Inc.盘中异动 早盘股价大涨5.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514851893","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514851893?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:54","pubTimestamp":1740581680,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时54分,Personalis, Inc.股票出现波动,股价快速上涨5.32%。Personalis, Inc.股票所在的生命科学行业中,整体涨幅为0.09%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。其产品包括ImmunoID NeXT, NeXT Personal, NeXT Dx Test和其他制药研究解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262254409893af8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502262254409893af8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PSNL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513343773","title":"Personalis, Inc.盘中异动 早盘股价大跌5.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513343773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513343773?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:15","pubTimestamp":1740410109,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时15分,Personalis, Inc.股票出现异动,股价急速下跌5.41%。Personalis, Inc.股票所在的生命科学行业中,整体涨幅为0.80%。Personalis, Inc.公司简介:Personalis Inc 是一家基因组测序和分析解决方案提供商,以支持个性化癌症疫苗和其他下一代癌症免疫疗法的开发。其产品包括ImmunoID NeXT, NeXT Personal, NeXT Dx Test和其他制药研究解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231510abdb1879&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224231510abdb1879&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PSNL","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.personalis.com","stockEarnings":[{"period":"1week","weight":-0.113},{"period":"1month","weight":0.2657},{"period":"3month","weight":1.1378},{"period":"6month","weight":0.3824},{"period":"1year","weight":1.1551},{"period":"ytd","weight":0.6759}],"compareEarnings":[{"period":"1week","weight":-0.0095},{"period":"1month","weight":-0.0062},{"period":"3month","weight":0.054},{"period":"6month","weight":0.0827},{"period":"1year","weight":0.1825},{"period":"ytd","weight":0.0882}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Personalis, Inc.于2011年2月21日在特拉华州注册成立,并于2011年9月开始运营。该公司是一家不断发展的癌症基因组学公司,通过提供有关每位患者癌症和免疫反应的更全面的分子数据,改变下一代疗法的发展。该公司设计其NeXT平台以适应对癌症的复杂和不断发展的理解,为其生物制药客户提供有关所有大约20,000个人类基因以及免疫系统的信息,而许多癌症小组覆盖大约50到500个基因。他们还在开发一种补充液体活检分析,分析所有人类基因与目前可用的更集中的液体活检分析。通过结合技术创新,运营规模和监管差异化,他们的NeXT平台旨在帮助他们的客户获得对治疗反应和抗药性机制以及新的潜在治疗目标的新见解。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.034852},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.039957},{"month":3,"riseRate":0,"avgChangeRate":-0.1526},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.039124},{"month":5,"riseRate":0.428571,"avgChangeRate":0.103651},{"month":6,"riseRate":0.714286,"avgChangeRate":0.089761},{"month":7,"riseRate":0.5,"avgChangeRate":0.242016},{"month":8,"riseRate":0.571429,"avgChangeRate":0.076793},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.07131},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.003099},{"month":11,"riseRate":0.428571,"avgChangeRate":0.014792},{"month":12,"riseRate":0.714286,"avgChangeRate":0.136788}],"exchange":"NASDAQ","name":"Personalis","nameEN":"Personalis"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Personalis(PSNL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Personalis(PSNL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Personalis,PSNL,Personalis股票,Personalis股票老虎,Personalis股票老虎国际,Personalis行情,Personalis股票行情,Personalis股价,Personalis股市,Personalis股票价格,Personalis股票交易,Personalis股票购买,Personalis股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Personalis(PSNL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Personalis(PSNL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}